Home › Companies › AVIDITY BIOSCIENCES INC. › 2024-2025

AVIDITY BIOSCIENCES INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and AVIDITY BIOSCIENCES INC.’s Form 8-K, filed 2025-06-10 (Item 5.07 on EDGAR). Page generated 04 October 2026.

7Reported items
245Asset managers
1,652Fund votes
2025-06-10Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AVIDITY BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by AVIDITY BIOSCIENCES INC.

These tallies are AVIDITY BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AVIDITY BIOSCIENCES INC. — official shareholder meeting results, meeting held 2025-06-10
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Arthur A. Levin, Ph.D.	107,228,713	--	--	3,977,391	5,546,736	Majority: yes
Elect Director: Simona Skerjanec	110,454,102	--	--	812,002	5,546,736	Majority: yes
Elect Director: Tamar Thompson	80,562,501	--	--	30,703,603	5,546,736	Majority: yes
Proposal 2: The ratification of the appointment of Deloitte & Touche, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.	116,729,544	31,495	51,801	--	0	Majority: yes
Proposal 3: The approval, on an advisory basis, of the compensation of the Company's named executive officers as described in the proxy statement related to the 2025 Annual Meeting.	80,649,100	25,309,060	5,307,944	--	5,546,736	Passed

Source: AVIDITY BIOSCIENCES INC., Form 8-K, filed with the SEC on 2025-06-10 — read the filing on EDGAR.

How asset managers voted at the AVIDITY BIOSCIENCES INC. 2024-2025 meeting

Each item below shows how the 245 asset managers that disclosed a AVIDITY BIOSCIENCES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AVIDITY BIOSCIENCES INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 7 wordings of this item as funds reported it.

76% Passed · of votes cast

FOR 76%AGAINST 24%

FOR: 80,649,100AGAINST: 25,309,060

AVIDITY BIOSCIENCES INC.’s own tally for this item (“Proposal 3: The approval, on an advisory basis, of the compensation of the Company's named executive officers as described in the proxy statement related to the 2025 Annual Meeting.”): 80,649,100 for, 25,309,060 against — passed, per its Form 8-K filed 2025-06-10 (Item 5.07). Of all 120,512,000 outstanding shares: 67% for, 21% against (88% of the company cast a for/against vote).

The 233 asset managers below cast 82% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 82%AGAINST 18%

FOR: 81.7%AGAINST: 18.3%ABSTAIN: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed” at AVIDITY BIOSCIENCES INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	25,343,408	2,494,044	For
T. Rowe Price	19,835,732	154,276	For
Vanguard	13,583,941	8,302	For
Janus Henderson	8,281,388	131,654	For
Wellington	8,046,214	0	For
BlackRock	467,529	5,530,790	Against
RTW INVESTMENTS, LP	5,989,346	0	For
Avoro Capital Advisors LLC	5,500,484	0	For
RA CAPITAL MANAGEMENT, L.P.	5,156,024	0	For
State Street	4,457,501	49,543	For
JANUS INVESTMENT FUND	4,290,266	0	For
GEODE CAPITAL MANAGEMENT, LLC	0	2,772,418	Against
Charles Schwab	797	2,071,534	Against
ORBIMED ADVISORS LLC	0	1,812,886	Against
Artisan	1,308,414	0	For
Siren, L.L.C.	1,110,610	0	For
Northern Trust	0	877,741	Against
PICTET ASSET MANAGEMENT SA	0	774,337	Against
Woodline Partners LP	750,678	0	For
Fiera Capital Corp	0	721,757	Against
Frazier Life Sciences Management, L.P.	625,000	0	For
Aberdeen	0	559,656	Against
Hartford	525,441	0	For
MPM BioImpact LLC	489,002	0	For
Voya	0	480,221	Against

Showing the 25 largest of 233 asset managers. See all 233 in the interactive database.

2. To ratify the appointment of Deloitte & Touche LLP as our independent public accounting firm for the fiscal year ending December 31, 2025;

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 116,729,544AGAINST: 31,495

AVIDITY BIOSCIENCES INC.’s own tally for this item (“Proposal 2: The ratification of the appointment of Deloitte & Touche, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 116,729,544 for, 31,495 against, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 120,512,000 outstanding shares: 97% for, 0.1% against (97% of the company cast a for/against vote).

The 74 asset managers below cast 99.9% of the shares they voted on this item FOR (49,365,186 for, 1,367 against).

FOR 99.9%

FOR: 49,365,186 (100.0%)AGAINST: 1,367 (0.0%)ABSTAIN: 7,237 (0.0%)NOT VOTED: 65 (0.0%)

Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as our independent public accounting firm for the fiscal ye” at AVIDITY BIOSCIENCES INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	13,263,537	0	For
Fidelity	12,547,206	0	For
T. Rowe Price	8,591,121	0	For
JANUS INVESTMENT FUND	4,290,266	0	For
BlackRock	3,214,528	0	For
State Street	1,166,257	0	For
Charles Schwab	1,033,513	0	For
Artisan	632,904	0	For
Hartford	525,441	0	For
MUTUAL FUND SERIES TRUST	375,924	0	For
Equitable	340,789	0	For
TIAA	332,530	0	For
Aberdeen	279,828	0	For
Voya	203,082	0	For
Lincoln Financial	185,563	0	For
Brighthouse	172,092	7,237	For
MoA Funds Corp	161,006	0	For
John Hancock	140,017	0	For
DRIEHAUS MUTUAL FUNDS	134,009	0	For
New York Life	130,634	0	For
Northwestern Mutual	128,227	0	For
Simplify Exchange Traded Funds	125,000	0	For
Global X	124,100	0	For
QUANTITATIVE MASTER SERIES LLC	118,347	0	For
ALPS ETF Trust	87,664	0	For

Showing the 25 largest of 74 asset managers. See all 74 in the interactive database.

3. To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Arthur Levin, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 107,228,713WITHHELD: 3,977,391

AVIDITY BIOSCIENCES INC.’s own tally for this item (“Elect Director: Arthur A. Levin, Ph.D.”): 107,228,713 for, 3,977,391 withheld, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 120,512,000 outstanding shares: 89% for, 3% withheld (92% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (47,830,271 for, 0 against).

FOR 97%

FOR: 47,830,271 (97.1%)ABSTAIN: 1,418,519 (2.9%)NOT VOTED: 65 (0.0%)

Largest asset managers voting on “To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and ” at AVIDITY BIOSCIENCES INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	13,263,537	0	For
Fidelity	12,547,206	0	For
T. Rowe Price	8,591,121	0	For
JANUS INVESTMENT FUND	4,290,266	0	For
BlackRock	3,214,528	0	For
State Street	4,361	1,161,896	Abstain
Charles Schwab	1,033,513	0	For
Artisan	632,904	0	For
Hartford	525,441	0	For
MUTUAL FUND SERIES TRUST	375,924	0	For
Equitable	215,219	125,570	For
TIAA	332,530	0	For
Aberdeen	279,828	0	For
Voya	203,082	0	For
Lincoln Financial	97,060	88,503	For
Brighthouse	172,092	7,237	For
MoA Funds Corp	161,006	0	For
John Hancock	140,017	0	For
DRIEHAUS MUTUAL FUNDS	134,009	0	For
New York Life	130,634	0	For
Northwestern Mutual	128,227	0	For
Global X	124,100	0	For
QUANTITATIVE MASTER SERIES LLC	118,347	0	For
ALPS ETF Trust	87,664	0	For
Jackson National	72,877	8,133	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

4. To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Simona Skerjanec

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 110,454,102WITHHELD: 812,002

AVIDITY BIOSCIENCES INC.’s own tally for this item (“Elect Director: Simona Skerjanec”): 110,454,102 for, 812,002 withheld, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 120,512,000 outstanding shares: 92% for, 0.7% withheld (92% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (49,082,176 for, 0 against).

FOR 99.6%

FOR: 49,082,176 (99.7%)ABSTAIN: 166,614 (0.3%)NOT VOTED: 65 (0.0%)

Largest asset managers voting on “To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and ” at AVIDITY BIOSCIENCES INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	13,263,537	0	For
Fidelity	12,547,206	0	For
T. Rowe Price	8,591,121	0	For
JANUS INVESTMENT FUND	4,290,266	0	For
BlackRock	3,214,528	0	For
State Street	1,166,257	0	For
Charles Schwab	1,033,513	0	For
Artisan	632,904	0	For
Hartford	525,441	0	For
MUTUAL FUND SERIES TRUST	375,924	0	For
Equitable	215,219	125,570	For
TIAA	332,530	0	For
Aberdeen	279,828	0	For
Voya	203,082	0	For
Lincoln Financial	180,560	5,003	For
Brighthouse	172,092	7,237	For
MoA Funds Corp	161,006	0	For
John Hancock	140,017	0	For
DRIEHAUS MUTUAL FUNDS	134,009	0	For
New York Life	130,634	0	For
Northwestern Mutual	128,227	0	For
Global X	124,100	0	For
QUANTITATIVE MASTER SERIES LLC	118,347	0	For
ALPS ETF Trust	87,664	0	For
Jackson National	72,877	8,133	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

5. To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Tamar Thompson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%WITHHELD 28%

FOR: 80,562,501WITHHELD: 30,703,603

AVIDITY BIOSCIENCES INC.’s own tally for this item (“Elect Director: Tamar Thompson”): 80,562,501 for, 30,703,603 withheld, per its Form 8-K filed 2025-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 120,512,000 outstanding shares: 67% for, 25% withheld (92% of the company cast a for/withheld vote).

The 71 asset managers below cast 100% of the shares they voted on this item FOR (38,090,315 for, 0 against).

FOR 77%ABSTAIN 23%

FOR: 38,090,315 (77.3%)ABSTAIN: 11,158,475 (22.7%)NOT VOTED: 65 (0.0%)

Largest asset managers voting on “To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and ” at AVIDITY BIOSCIENCES INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	13,262,597	940	For
Fidelity	12,510,143	37,063	For
T. Rowe Price	8,591,121	0	For
JANUS INVESTMENT FUND	0	4,290,266	Abstain
BlackRock	0	3,214,528	Abstain
State Street	2,929	1,163,328	Abstain
Charles Schwab	1,033,389	125	For
Artisan	632,904	0	For
Hartford	525,441	0	For
MUTUAL FUND SERIES TRUST	375,924	0	For
Equitable	34,639	306,150	Abstain
TIAA	332,530	0	For
Aberdeen	0	279,828	Abstain
Voya	0	203,082	Abstain
Lincoln Financial	37,000	148,563	Abstain
Brighthouse	131,297	48,032	For
MoA Funds Corp	0	161,006	Abstain
John Hancock	100,574	39,443	For
DRIEHAUS MUTUAL FUNDS	0	134,009	Abstain
New York Life	130,634	0	For
Northwestern Mutual	128,227	0	For
Global X	0	124,100	Abstain
QUANTITATIVE MASTER SERIES LLC	0	118,347	Abstain
ALPS ETF Trust	0	87,664	Abstain
Jackson National	0	81,010	Abstain

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 3 wordings of this item as funds reported it.

76% Passed · of votes cast

FOR 76%AGAINST 24%

FOR: 80,649,100AGAINST: 25,309,060

The 9 asset managers below cast 14% of the shares they voted on this item FOR (359,589 for, 2,239,705 against).

13%AGAINST 82%

FOR: 359,589 (13.2%)AGAINST: 2,239,705 (82.2%)ABSTAIN: 125,000 (4.6%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at AVIDITY BIOSCIENCES INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	1,947,074	0	Against
JPMorgan	359,570	0	0	For
EFG Asset Management (North America) Corp.	0	169,978	0	Against
Simplify Exchange Traded Funds	0	0	125,000	Abstain
Desjardins Global Asset Management Inc.	0	121,653	0	Against
TD Waterhouse Canada Inc.	0	1,000	0	Against
Coyle Financial Counsel LLC	19	0	0	For
Jaffetilchin Investment Partners, LLC	0	0	0	--
Trivant Custom Portfolio Group, LLC	0	0	0	--

Showing the 6 reported items with the widest manager coverage, of 7 in total. View every item.

Largest AVIDITY BIOSCIENCES INC. shareholders voting in 2024-2025

Ranked by the number of AVIDITY BIOSCIENCES INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 120,512,000 shares outstanding at the time of that meeting.

Top AVIDITY BIOSCIENCES INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Fidelity	23.10%
2	T. Rowe Price	16.59%
3	Vanguard	11.28%
4	Janus Henderson	6.98%
5	Wellington	6.68%
6	BlackRock	4.98%
7	RTW INVESTMENTS, LP	4.97%
8	Avoro Capital Advisors LLC	4.56%
9	RA CAPITAL MANAGEMENT, L.P.	4.28%
10	State Street	3.74%

Reported AVIDITY BIOSCIENCES INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

AVIDITY BIOSCIENCES INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	12.96%	13F
T. Rowe Price	9.41%	13F
FMR LLC	8.63%	DEF14A
Avoro Capital Advisors LLC	8.24%	DEF14A
BlackRock	8.23%	13F
Wellington Management	8.04%	13F
Vanguard Group	7.67%	13F
JANUS HENDERSON GROUP PLC	5.76%	13G
RA Capital Management, L.P.	5.23%	DEF14A
RTW Investments, LP	3.89%	13D

Percentages above are of 120,512,000 shares outstanding, as reported by AVIDITY BIOSCIENCES INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AVIDITY BIOSCIENCES INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At AVIDITY BIOSCIENCES INC.'s shareholder meeting held 2025-06-10, in the 2024-2025 proxy season, 245 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,652 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To consider and vote upon, on an advisory basis, the compensation of our named executive… — the proposal passed with 76% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AVIDITY BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-10.

AVIDITY BIOSCIENCES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.